| CAS NO: | 18323-44-9 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| 1g | 电议 |
| 5g | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 424.98 |
| Cas No. | 18323-44-9 |
| Formula | C18H33ClN2O5S |
| Solubility | insoluble in EtOH; ≥15.3 mg/mL in DMSO; ≥50.6 mg/mL in H2O |
| Chemical Name | (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide |
| Canonical SMILES | CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| Animal experiment:[1] | |
Animal models | BALB/cJ mice infected with influenza virus and superinfected withStreptococcus pneumonia(S. pneumoniae) |
Dosage form | 60 mg/kg Twice daily by intraperitoneal route for 7 days |
Applications | In the model, clindamycin therapy used either alone (survival rate, 82%) or in combination with ampicillin (80%) performed significantly better than ampicillin therapy (56%). Improved survival appeared to be mediated by decreased inflammation manifested as lower levels of inflammatory cells and proinflammatory cytokines in the lungs and by observation of less-severe histopathologic findings. Thus, treatment with protein synthesis inhibitor clindamycin could improve outcomes of secondary bacterial pneumonia after influenza. |
Note | The technical data provided above is for reference only. |
References: 1. Karlstrom A, Boyd KL, English BK, et al. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. The Journal of Infectious Diseases, 2009, 199(3): 311-319. | |
m.cnreagent.com